Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2013 - New Study Released
Global Markets Direct's, 'Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia). Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, Half...
View full press release